L. Reuteri ATCC PTA 5289 & L. Reuteri DSM 17938 for the Treatment of Children With Pharyngitis and/or Tonsillitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-28

Study Completion Date

2019-02-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RCT in children (6m to 5y) with pharyngitis and/or tonsillitis who will be allocated to receive for 10 days L. reuteri DSM 17938 + L. reuteri ATCC PTA 5289) at a dose of 2x10\^8 Colony Forming Units (CFU). Five drops are to be taken twice a day (in the morning and in the evening) or placebo drops, as treatment for clinical condition. Duration of symptoms and reduction of pain (odynophagia) severity during treatment will be measured as primary outcome

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Inflammatory Symptoms Reduction With Amoxicillin + Ketoprofen in Acute Pharyngeal Tonsillitis in Pediatric Patients

NCT00799838

Pharyngotonsillitis

TERMINATED PHASE4

A Trial Of Azithromycin SR For The Treatment Of Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis

NCT00393835

Upper Respiratory Tract Infection

COMPLETED PHASE3

Efficacy Study of Pristinamycin Versus Amoxicillin to Treat Tonsillitis Induced by Streptococcus in Children

NCT00393744

Tonsillitis

COMPLETED PHASE3

Multicenter, Open, Randomized Comparative Trial To Compare The Efficacy Of Azithromycin Versus Amoxicillin In Children With Strep Throat

NCT00643539

Tonsillitis

COMPLETED PHASE4

Compliance And Safety Study In Children With Upper And Lower Respiratory Tract Infections

NCT00939185

Respiratory Tract Infections

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rationale. Acute respiratory infections (ARIs) are a common problem in the first decade of life. The yearly prevalence of respiratory tract infections in an otherwise healthy 3-year old child is about three to 10 infections. Children between 6 months and 5 years are more prone to develop pharyngitis and tonsillitis compared to older children. 60-70% of children with F/T lies within this age group. Aetiology the pharyngitis and tonsillitis is viral in 70% of all cases In developing countries 6/10 cases are treated using antibiotics, regardless of clinical guidelines or standard of care documents recommending only to use symptomatic drugs (NSAID).

Primary outcome. Duration of symptoms and reduction of pain (odynophagia) severity Secondary outcomes. Days with fever secondary to RTIs; Number of children receiving antibiotic treatment in each treatment group; Days of medical office visits or emergency visits; Total amount of medical office visits or emergency visits during the study, secondary to episodes of RTI; Days of absences from day care centre; Direct and Indirect costs Total costs of treatments including visit to private office, visit to emergency department, cost of treatment (NSAIDs + Probiotics vs NSAIDs + Placebo); Frequency of adverse events; Viral/bacterial load (multiplex-PCR); IgA in saliva and Change in salivary inflammatory biomarkers.

Interventions. L. reuteri DSM 17938 + L. reuteri ATCC PTA 5289) will be given at a dose of 2x10\^8 Colony Forming Units (CFU). Five drops are to be taken twice a day (in the morning and in the evening) giving a daily dose of 4x108 CFU/day. The placebo drops will have identical ingredients except for lacking the bacteria. Five drops are to be taken twice a day (in the morning and in the evening).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pharyngitis Tonsillitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized controlled trial, double blind allocation concealment, parallel assignment

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Randomization list will by assembled by independient organization not related with participant, care provider, investigators or sponsors. eCRF will include randomization selection

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Probiotic

L. reuteri ATCC PTA 5289 + L. reuteri DSM 17938 at a dose of 2x10\^8 Colony Forming Units (CFU)

Group Type EXPERIMENTAL

Probiotic

Intervention Type DIETARY_SUPPLEMENT

L. reuteri Prodentis oil drops (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289) will be given at a dose of 2x108 Colony Forming Units (CFU). Five drops are to be taken twice a day (in the morning and in the evening) giving a daily dose of 4x108 CFU/day.

Placebo

Five drops of Placebo taken twice a day (in the morning and in the evening).

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Five drops of Placebo taken twice a day (in the morning and in the evening).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Probiotic

L. reuteri Prodentis oil drops (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289) will be given at a dose of 2x108 Colony Forming Units (CFU). Five drops are to be taken twice a day (in the morning and in the evening) giving a daily dose of 4x108 CFU/day.

Intervention Type DIETARY_SUPPLEMENT

Placebo

Five drops of Placebo taken twice a day (in the morning and in the evening).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy Infants suffering from pharyngitis and/or tonsillitis
* Born at term (36 weeks of gestation)
* Any gender
* 6 months to 5 years old
* Birth weight \>2500 g
* Same socioeconomic background
* Written informed consent from at least one parent or legal guardian

Exclusion Criteria

* Use of antibiotics or probiotic products 2 weeks' prior inclusion in the study
* Eight or more new ear infections (otitis media) within 12 months
* Two or more serious sinus infections within 12 months
* Two or more episodes of pneumonia within 12 months
* Two or more invasive infections in the history (meningitis, cellulitis, osteomyelitis, septicaemia)
* Failure to gain weight or grow normally
* Chronic diarrhoea
* Recurrent deep skin or organ abscesses,
* Persistent superficial candidiasis after 1 year of age
* Use of two or more months on antibiotics for respiratory infections on the last year before considered eligible
* Gastroesophageal reflux
* Allergy
* Asthma
* A1-antitrypsin deficeincy
* Primary or secondary ciliary dyskenisia
* Congenital anomalies of respiratory tract
* Supplementation of probiotics 2 weeks before inclusion in the study and during the whole study period
* If the mother is breastfeeding the child participating in the trial the mother should not use supplementation of probiotics 2 weeks before and during the study period
* Concurrent participation in other clinical trials

Minimum Eligible Age

6 Months

Maximum Eligible Age

5 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No